NCT01511289View on ClinicalTrials.gov

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

February 28, 2015

Conditions
LeukemiaLeukemia, MyeloidLeukemia, Myelogenous, Chronic, BCR-ABL PositivePhiladelphia ChromosomeBone Marrow DiseasesHematologic Diseases
Interventions
DRUG

Imatinib

400mg/Tab, QD

DRUG

Radotinib

100mg or 200mg/Capsule, 300mg or 400mg BID

Trial Locations (22)

Unknown

Local Institution, Jakarta

Local Institution, Batangas

Local Institution, Manila

Local Institution, Bangkok

602-715

Local Institution, Busan

602-739

Local Institution, Busan

633-165

Local Institution, Busan

700-712

Local Institution, Daegu

301-721

Local Institution, Daejeon

431-070

Local Institution, Gyeonggi-do

442-723

Local Institution, Gyeonggi-do

443-721

Local Institution, Gyeonggi-do

405-760

Local Institution, Incheon

561-712

Local Institution, Jeollabuk-do

519-763

Local Institution, Jeonnam

110-746

Local Institution, Seoul

137-701

Local Institution, Seoul

138-736

Local Institution, Seoul

152-703

Local Institution, Seoul

158-710

Local Institution, Seoul

682-714

Local Institution, Ulsan

220-701

Local Institution, Wŏnju

All Listed Sponsors
lead

Il-Yang Pharm. Co., Ltd.

INDUSTRY

NCT01511289 - Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | Biotech Hunter | Biotech Hunter